From ELLE
Martha* looks expensive. Not freshly minted footballers wife expensive. Not bouncy-haired ladies who dont lunch expensive. But quietly expensive: skin that glimmers like the Cullinan Diamond; a body as smooth as Carrara marble. Just unmistakably well crafted. And so she should: the 34-year-old luxury retailer spends almost 4,000 a month thats how much it costs to be tweaked and perfected by the latest advances in health.
Theres the weekly three-minute cryotherapy sessions at 100 a pop. Then theres the 125 personal training workouts, of which she has four each week. Theres also the mandatory 150 monthly vitamin drip and at least one massage a fortnight (call it 160), as well as a personalised supplement plan that seems a bargain at 50 per week. Thats around 4,000, including the cryo, but not including facials and beauty things, of course, she says. Of course. And, to be fair, its working for her. With her plump, practically line-free face, and raven hair so shiny you could almost reapply your lipstick in front of it, she is a walking advertisement for the power of whacking a hefty monthly mortgage payment at your health.
Photo credit: Luca Cannonieri
But how much is good health really worth? Apparently, when youre part of the super-rich set, the answer is: a lot. When UBS investment bank surveyed its millionaires, nine out of ten agreed that health is more important than wealth with its highest earners willing to give up half of their fortune to guarantee an extra decade of good health. Because when you have everything money can buy, what you really want is the one thing it cant. Until now.
An entire industry has sprung up over the past decade, catering largely to the wealthiest 1%, but also to mere fiscal mortals, too, who aspire to perfect health in the way they once aspired to own a Birkin bag. Take last years two-day Goop conference, where doctors, scientists and health-mad celebrities took to the stage at Londons Re:Centre sanctuary. A one-day ticket set visitors back 1,000. But for a two-day, full-access pass with VIP workouts and a room at the shiny new Kimpton Fitzroy Hotel? Try 4,500.(According to Goop, all of these full-access tickets sold out.)
Or take the new offering from the exclusive Arts Club in London, which has teamed up with Lanserhof, the almost mythical Austrian health retreat that has been peddling longevity and luminosity for decades. Now, those members can pay 6,500 a year (non-members will have to cough up an extra 1,500) to have access to their on-site Lanserhof clinic. For that they can throw as much at their health and body as they like, with MRI scans, DNA tests, osteopathy sessions, shock wave therapy, acupuncture treatments... the list goes on. And on.
At the top end of the health scale, however, the sky is the limit. At RAAD fest, an annual conference held in the US attended by many of the worlds leading billionaires, a number of scientists and technologists parade the latest evolutions in healthcare. They are dystopian-sounding technologies, such as hyperbaric oxygen chambers that offer expediated healing, as well as stem cell IV infusions (yours for around 875 a pop).
Photo credit: Alessandro Zeno - Imaxtree
Story continues
What do they all have in common? A big price tag and the promise of immortality. After all, RAAD stands for The Revolution Against Ageing and Death, and is organised by the controversial Coalition for Radical Life Extension. Their mission: to help the super-rich dispose of their money before they hit their graves.But, ideally for them, not to hit their tombstones... ever.
Dr Sabine Donnai is the founder of private health service Viavi and creator of its Health Assessment and HealthStrategy, seen as the Aston Martin of health programmes. Donnai, previously the medical director at Nuffield Health Wellbeing, saw a gap in the market for an assessment that went beyond the norm. The market was there. Theyve worked hard, theyve made money and now they ask, I want to continue enjoying this, so what do I do?, she explains. They want the data. They want the control. They want to understand what their health looks like.
Her clientele is split into two groups. The first: the worried well, seeking preventive measures. They come to us to understand a thorough picture of their health and what they can do to improve it, says Donnai. For example, a hormone test might reveal underlying reasons for weight gain, or a toxin level result might expose risks to your immune system. The second, smaller group have been diagnosed with a problem, but want to solve it rather than treat it. The difference is important. Say they have cancer we arent oncologists or surgeons, but our role might be to identify how they could prevent it from returning. They dont want to be hassled by illness, says Donnai. But want to live a better life.
Viavis assessment can go as far as the client chooses. In a single day, you can have everything from a transvaginal scan and breast ultrasound to a urine hormone screen and toxic body burden test. When I ask one client, an international business owner in her forties, why she chose to invest in the test, she says, Its the best. Its hard to put a price on it... she trails off. Viavi, however, is happy to do so: the full Health Assessment and Health Strategy costs 15,000.
On the other side of the city, Workshop Gymnasium is doing for fitness what Viavi is doing for health: catering to the demands of the richest 1%. Hidden in Knightsbridge, beneath the Bvlgari Hotel, it looks more like a hedge fund managers apartment than a gym, with wooden floors, honeyed lighting and towers of glossy green apples beside fans of shiny magazines.
Its top-tier membership will set you back 13,000 a year. There are also add-ons, including supplements and physiotherapy, pushing some members spend past the 20,000 mark. Its where Martha splurges on her 125 an hour PT sessions with founder Lee Mullins, who reports increasing interest in his services from around the world. (Workshop has locations in China, Milan, Dubai and Bali.) They want a customised approach and come for the assessments we offer to tailor their programme, he says of his client base of CEOs, entertainment industry types and models.
They also get training on demand Workshop offers a 24/7 service, in a private setting if requested, with total discretion. Mullins is tight-lipped about his celebrity clients, save a handful of models, including brand ambassadors Amelia Windsor, Clara Paget and Eliza Cummings. Clients can even have a trainer travel with them on business trips or holidays for a fee of up to 2,000 per day.
There are options for those with slightly less disposable income. At BelleCell, a biohacking clinic next to The Ritz London, packages are available at varying levels. Set in a 500-year-old vault, comprising a series of spaceship-like pods, it serves to optimise cell performance and recovery and offer effective health solutions total wellbeing on a molecular level. Which, in English, means they claim to make you better, stronger and healthier. This includes full bio-analysis tests and cell-optimising treatments (oxygen pods, vitamin infusions, alien-esque capsules in which to exercise). The top package, a Genetic Test for Life, will set you back almost 3,000, but therapies start from 110 in order to be accessible to everyone, says founder Kasia Zajkowska, a former molecular bio-scientist. Well, maybe not exactly everyone...
Dropping up to 15,000 on a health test attracts a specific section of the super-wealthy, one thats already aware and selective about wellness, says Zajkowska. She claims theyre not doing it for vanity: Their choice to spend is for the most part not about aesthetics, but future proofing. For some, the investment in themselves does come with more of a beauty focus. Carrie, a 51-year-old property business company director, who lives in Cheshire, tells me that yes, she goes to the gym and takes supplements for health and longevity, but she wants to look better, too. She spends almost 10,000 a year on aesthetics alone (monthly facials, radio frequency and micro needling) money that is more than pocket-change to her. But shes willing to prioritise the spend for the results.
For many, even a single treatment at one of these clinics would be a luxury or an impossibility. Never mind a super-screening that costs more than some house deposits. But in England, with the NHS available to all, are they even necessary? Women are offered free cervical screening from the age of 25, free breast screening from 50 and a free NHS health check from 40. This extensive check looks for early signs of high blood pressure, diabetes, kidney disease, heart disease and dementia. And, according to former NHS GP Dr Juliet McGrattan, it could be the better option, even when you do have money to blow, due to the legitimacy of the tests.
Photo credit: Astrid Stawiarz
With any screening test, there is a possibility that a false positive (when something is detected that isnt actually a problem) or a false negative (when something is missed) may occur, she tells me. The NHS has meticulously evaluated its offering to try to ensure it has the lowest number of these results. Her worry is that private tests may not have been so thoroughly evaluated. She adds that private companies cant always offer care beyond the test, so you might be directed to your NHS GP anyway. In her opinion, theres no need to part with money.
As for Martha, her 4,000 monthly investment is about boosting energy, feeling better and staying strong, something us mere mortals can relate to as we weave a rather less extortionate version of wellness into our daily lives. But she admits, Appearances matter. I have to look the part and be seen to be taking part. It seems that consumption isnt always so inconspicuous after all.
*Name has been changed
You Might Also Like
Read more from the original source:
Meet The Super-Rich Spending 4,000 A Month On Their Health - Yahoo Style
- BIORESTORATIVE THERAPIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) - Marketscreener.com - March 29th, 2023
- Induced Pluripotent Stem Cell for the Study and Treatment of ... - Hindawi - December 3rd, 2022
- What Happens When Everyone Realises We Can Live Much Longer? We May Find Out As Soon As 2025 - Forbes - December 3rd, 2022
- INTERNATIONAL STEM CELL CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - November 17th, 2022
- 3D Cell Culture Market stands at revenue of US$ 1.15 Bn in 2022, and is predicted to surge at a CAGR of 9.8% to hit worth of US$ 2.67 Bn during... - November 17th, 2022
- YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - November 17th, 2022
- ACTINIUM PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q) - Marketscreener.com - November 17th, 2022
- Top 10 Best Stem Cell Supplement Brands - Healthtrends - June 26th, 2022
- How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM - June 26th, 2022
- Stem Cell Wellness Kit - June 26th, 2022
- Kangstem Biotech withdraws trial application for stem cell-based osteoarthritis treatment - KBR - June 26th, 2022
- Global Human Embryonic Stem Cell Market to be Driven by the Rapid Technological Advancements in the Forecast Period of 2022-2027 Designer Women -... - June 26th, 2022
- Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the... - June 26th, 2022
- Efficient terminal erythroid differentiation requires the APC/C cofactor Cdh1 to limit replicative stress in erythroblasts | Scientific Reports -... - June 26th, 2022
- Propanc Biopharma's CSO Hails Dostarlimab's Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer - Business Wire - June 26th, 2022
- Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including... - June 26th, 2022
- 10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomes - Targeted Oncology - June 26th, 2022
- Embryonic Stem Cell Research: An Ethical Dilemma - January 30th, 2022
- Skeletal Muscle Cell Induction from Pluripotent Stem Cells - January 30th, 2022
- mRNA COVID-19 Vaccine Effectiveness in the Immunocompromised - Medscape - January 30th, 2022
- MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study - Business... - January 30th, 2022
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following... - January 30th, 2022
- Targeted Therapy Innovator Foresees New Paradigms in Breast Cancer - OncLive - January 30th, 2022
- Global Circulating Tumor Cells (CTC) Market Growing Demand, Future Trends, Competitive Regions and Forecast 2021 to 2027 The Oxford Spokesman - The... - January 30th, 2022
- Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer |... - December 8th, 2021
- All at-risk TN-bound travellers test Covid negative - The New Indian Express - December 8th, 2021
- Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out - FW Business - December 8th, 2021
- Pandemic lockdown declined emotional well-being for adults with hearing, vision loss: Study - ETHealthworld.com - December 8th, 2021
- Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India -... - August 17th, 2021
- Longeveron: Time to Buy the Di - GuruFocus.com - August 17th, 2021
- The latest on the Covid-19 pandemic in the US: Live updates - CNN - August 17th, 2021
- How this Holocaust refugee beat Covid-19 against all odds J. - The Jewish News of Northern California - August 17th, 2021
- Trade-offs among transport, support, and storage in xylem from shrubs in a semiarid chaparral environment tested with structural equation modeling -... - August 17th, 2021
- Oklahoma 10-year-old in remission after being diagnosed with rare form of leukemia 2 years ago - KFOR Oklahoma City - July 21st, 2021
- Covid: There's a serious problem with how we are testing people for the virus Neale Hanvey MP - The Scotsman - July 21st, 2021
- Profilin 1 Protein and Its Implications for Cancers - Cancer Network - July 21st, 2021
- Homing Technology Delivers Therapy to Cancerous Bone - The Scientist - July 21st, 2021
- Developmental Interest in Allogeneic PlacentaDerived Cell Therapies Expands - OncLive - July 21st, 2021
- Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches - DocWire News - July 21st, 2021
- The World's First Lab-Grown Foie Gras Could Solve This Major Concern - Mashed - July 21st, 2021
- KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free... - July 21st, 2021
- Human Mesenchymal Stem Cells (hMSC) Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv... - March 3rd, 2021
- [Full text] An Update on the Molecular Pathology of Metaplastic Breast Cancer | BCTT - Dove Medical Press - March 3rd, 2021
- 4D Pharma Appointments Paul Maier to the Board as Non-Executive Director - Business Wire - March 3rd, 2021
- Investigative Interventions Gain Ground in GVHD - OncLive - March 3rd, 2021
- Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli - Targeted Oncology - March 3rd, 2021
- Martin Makes Sense of the Rapidly Evolving MCL Treatment Paradigm - OncLive - March 3rd, 2021
- Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment - BioSpace - March 3rd, 2021
- Health Matters; Inflammation with Dr. Baumgartner [PODCAST] - WJON News - February 14th, 2021
- G1 Therapeutics gains first FDA nod with myelopreservation therapy Cosela | 2021-02-12 - BioWorld Online - February 14th, 2021
- Kris Gopalakrishnan on innovation - Fortune India - February 14th, 2021
- Change is coming, and at an ever-accelerating pace - Al Jazeera English - January 12th, 2021
- MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval - OncLive - January 9th, 2021
- 5 questions facing gene therapy in 2021 - BioPharma Dive - January 9th, 2021
- RNA molecules are masters of their own destiny - MIT News - January 9th, 2021
- Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Industry Analysis and Forecast (2019-2026): By indication type, treatment type,... - January 9th, 2021
- Harpoon Therapeutics : Clin Cancer Res 2021; OnlineFirst version Jan 6, 2021 - Marketscreener.com - January 9th, 2021
- Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity - Science Advances - January 5th, 2021
- Versiti Blood Centers and Noodles & Company Serve Up Thanks to Blood Donors - PRNewswire - January 5th, 2021
- January 2021: 2020 Papers of the Year - Environmental Factor Newsletter - January 5th, 2021
- Ozone in the air is bad for birds - Massive Science - January 5th, 2021
- How good are the COVID-19 vaccines? - Massive Science - January 5th, 2021
- Stem cells from cord blood can now be used across many conditions: Mayur Abhaya, MD & CEO, LifeCell Internat.. - ETHealthworld.com - December 28th, 2020
- Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma - OncLive - December 28th, 2020
- CalvinAyre.com's most read life stories of 2020 - CalvinAyre.com - December 28th, 2020
- Coronavirus | Over 6,000 travellers from U.K. traced across States - The Hindu - December 28th, 2020
- Exosomes act as messengers and decoys to save healthy cells from viral infection - Massive Science - December 28th, 2020
- Celtics adjust to two-game series designed to reduce team travel - The Boston Globe - December 28th, 2020
- Experts Reflect on Most Impactful FDA Moves of 2020 in Solid Tumors, Hematologic Malignancies - Targeted Oncology - December 28th, 2020
- FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial... - December 28th, 2020
- Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145... - December 12th, 2020
- Daratumumab Regimen Shows Promise in Transplant-Eligible Patients With Newly Diagnosed Myeloma - Targeted Oncology - December 12th, 2020
- HSCT Found Potentially Curative for Some T-Cell Lymphoma Patients - Cancer Therapy Advisor - December 12th, 2020
- Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis - Yahoo Finance - December 12th, 2020
- ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple Myeloma - Cancer Network - December 12th, 2020
- BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute... - December 12th, 2020
- Flintshire youngster goes the extra mile to raise funds for Lymphoma Action | The Leader - LeaderLive - December 12th, 2020
- Meat-Tech Agrees to Acquire Cultured Fat Pioneer 'Peace of Meat' - PRNewswire - December 12th, 2020
- Stem Cell Manufacturing Market Size, Overview with Detailed Analysis, Competitive landscape, Forecast to 2027 - Cheshire Media - December 12th, 2020
- Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American... - December 12th, 2020